

Stock Code :1733

**Apex Biotechnology Corporation and
Subsidiaries**

**Consolidated Financial Statements for the
Six Months Ended June 30, 2026 and 2025 and
Independent Auditors' Review Report**

Notice to Readers

The reader is advised that these financial statements have been prepared originally in Chinese. In the event of a conflict between these financial statements and the original Chinese version or difference in interpretation between the two versions, the Chinese language financial statements shall prevail.

INDEPENDENT AUDITORS' REVIEW REPORT

The Board of Directors and Shareholders
Apex Biotechnology Corporation

Introduction

We have reviewed the accompanying consolidated balance sheets of Apex Biotechnology Corporation and its subsidiaries (collectively, the “Company”) as of June 30, 2026 and 2025, and the related consolidated statements of comprehensive income for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, the consolidated statement of changes in equity and cash flows for the six months ended June 30, 2026 and 2025, and the related notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Statement of Review Engagements of the Republic of China 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As disclosed in Note 11 to the consolidated financial statements, the financial statements of some non-significant subsidiaries included in the consolidated financial statements were not reviewed. As of June 30, 2026 and 2025, the combined total assets of these non-significant subsidiaries were NT\$21,890 thousand and NT\$13,436 thousand, respectively, representing 0.86% and 0.56%, respectively, of the consolidated total assets, and the combined total liabilities of these non-significant subsidiaries were NT\$7,948 thousand and NT\$7,090 thousand, respectively, representing 1.15% and 1.16%, respectively, of the consolidated total liabilities; for the three

months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, the amounts of combined comprehensive income of these subsidiaries were NT\$539 thousand, NT\$1,531 thousand, NT\$1,912 thousand and NT\$1,314 thousand, respectively, representing 1.46%, 6.29%, 1.60% and 1.51%, respectively, of the consolidated total comprehensive income.

Qualified Conclusion

Based on our reviews, except for the adjustments, if any, as might have been determined to be necessary had the financial statements of the non-significant subsidiaries as described in the preceding paragraph been reviewed, nothing has come to our attention that caused us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, consolidated financial position of the Company as of June 30, 2026 and 2025, and of its consolidated financial performance for the three months ended June 30, 2026 and 2025 and its consolidated financial performance and its consolidated cash flows for the six months ended June 30, 2026 and 2025 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors’ review report are Ya Yun Chang and Ming Hui Chen.

Deloitte & Touche
Taipei, Taiwan
Republic of China

August 7, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors’ review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors’ review report and consolidated financial statements shall prevail.

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (In Thousands of New Taiwan Dollars)

ASSETS	June 30, 2026		December 31, 2025		June 30, 2025	
	Amount	%	Amount	%	Amount	%
Current assets						
Cash (Note 6)	\$ 737,658	29	\$ 567,091	24	\$ 583,496	24
Financial assets at fair value through profit or loss – current (Notes 7 and 27)	77,193	3	77,275	3	91,242	4
Notes and accounts receivable, net (Notes 9, 21 and 28)	399,131	16	437,799	18	408,011	17
Other receivables (Note 9)	8,270	-	9,806	-	9,503	-
Inventories (Note 10)	592,647	23	561,834	23	540,299	23
Other current assets (Note 15)	<u>16,747</u>	<u>1</u>	<u>19,793</u>	<u>1</u>	<u>18,442</u>	<u>1</u>
Total current assets	<u>1,831,646</u>	<u>72</u>	<u>1,673,598</u>	<u>69</u>	<u>1,650,993</u>	<u>69</u>
Non-current assets						
Financial assets at amortized cost - non-current (Notes 8 and 29)	6,200	-	6,200	-	6,200	-
Property, plant and equipment (Note 12)	537,960	21	552,203	23	565,556	24
Right-of-use assets (Note 13)	96,866	4	100,440	4	104,890	4
Intangible assets (Note 14)	33,296	1	35,710	2	34,959	2
Deferred tax assets (Notes 4 and 23)	4,243	-	12,795	1	6,071	-
Prepayments for business facilities	8,783	1	2,926	-	4,705	-
Refundable deposits	3,906	-	4,079	-	4,339	-
Net defined benefit asset, non-current (Notes 4 and 19)	<u>27,754</u>	<u>1</u>	<u>27,854</u>	<u>1</u>	<u>23,881</u>	<u>1</u>
Total non-current assets	<u>719,008</u>	<u>28</u>	<u>742,207</u>	<u>31</u>	<u>750,601</u>	<u>31</u>
Total assets	<u>\$ 2,550,654</u>	<u>100</u>	<u>\$ 2,415,805</u>	<u>100</u>	<u>\$ 2,401,594</u>	<u>100</u>
LIABILITIES AND EQUITY	June 30, 2026		December 31, 2025		June 30, 2025	
	Amount	%	Amount	%	Amount	%
Current liabilities						
Contract liabilities - current (Note 21)	14,436	1	7,233	-	13,797	1
Notes payable (Note 16)	37,666	1	39,187	2	34,491	1
Accounts payable (Notes 16 and 28)	192,298	8	192,508	8	154,745	7
Dividends payable (Note 20)	129,935	5	-	-	119,940	5
Other payables (Note 17)	161,731	6	144,308	6	127,360	5
Current tax liabilities (Notes 4 and 23)	30,823	1	25,876	1	25,916	1
Current provisions (Note 18)	13,304	1	12,180	1	13,107	1
Lease liabilities - current (Note 13)	5,760	-	7,692	-	8,485	-
Other current liabilities (Note 17)	<u>2,955</u>	<u>-</u>	<u>3,062</u>	<u>-</u>	<u>2,935</u>	<u>-</u>
Total current liabilities	<u>588,908</u>	<u>23</u>	<u>432,046</u>	<u>18</u>	<u>500,776</u>	<u>21</u>
Non-current liabilities						
Deferred tax liabilities (Notes 4 and 23)	845	-	10,819	1	4,080	-
Lease liabilities - non-current (Note 13)	100,686	4	101,982	4	105,207	4
Guarantee deposits received	<u>488</u>	<u>-</u>	<u>468</u>	<u>-</u>	<u>425</u>	<u>-</u>
Total non-current liabilities	<u>102,019</u>	<u>4</u>	<u>113,269</u>	<u>5</u>	<u>109,712</u>	<u>4</u>
Total liabilities	<u>690,927</u>	<u>27</u>	<u>545,315</u>	<u>23</u>	<u>610,488</u>	<u>25</u>
Equity attributable to shareholders of the parent (Note 20)						
Share capital						
Ordinary shares	<u>999,502</u>	<u>39</u>	<u>999,502</u>	<u>41</u>	<u>999,502</u>	<u>42</u>
Capital surplus	<u>68,368</u>	<u>3</u>	<u>68,368</u>	<u>3</u>	<u>68,368</u>	<u>3</u>
Retained earnings						
Legal reserve	558,319	22	541,607	23	541,607	23
Unappropriated earnings	<u>221,035</u>	<u>9</u>	<u>249,627</u>	<u>10</u>	<u>173,188</u>	<u>7</u>
Total retained earnings	<u>779,354</u>	<u>31</u>	<u>791,234</u>	<u>33</u>	<u>714,795</u>	<u>30</u>
Other equity	<u>11,543</u>	<u>-</u>	<u>10,612</u>	<u>-</u>	<u>7,803</u>	<u>-</u>
Equity attributable to shareholders of the parent	1,858,767	73	1,869,716	77	1,790,468	75
Non-controlling interests (Note 20)	<u>960</u>	<u>-</u>	<u>774</u>	<u>-</u>	<u>638</u>	<u>-</u>
Total equity	<u>1,859,727</u>	<u>73</u>	<u>1,870,490</u>	<u>77</u>	<u>1,791,106</u>	<u>75</u>
Total liabilities and equity	<u>\$ 2,550,654</u>	<u>100</u>	<u>\$ 2,415,805</u>	<u>100</u>	<u>\$ 2,401,594</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.
(With Deloitte & Touche review report dated August 7, 2026)

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended June 30				For the Six Months Ended June 30			
	2026		2025		2026		2025	
	Amount	%	Amount	%	Amount	%	Amount	%
NET OPERATING REVENUE								
(Notes 21 and 28)	\$ 470,653	100	\$ 509,948	100	\$ 990,376	100	\$ 1,068,701	100
OPERATING COSTS								
(Notes 10、22 and 28)	<u>312,366</u>	<u>66</u>	<u>373,048</u>	<u>73</u>	<u>656,425</u>	<u>66</u>	<u>769,142</u>	<u>72</u>
GROSS PROFIT	<u>158,287</u>	<u>34</u>	<u>136,900</u>	<u>27</u>	<u>333,951</u>	<u>34</u>	<u>299,559</u>	<u>28</u>
OPERATING EXPENSES (Notes 9、22 and 28)								
Selling and marketing expenses	30,156	6	24,655	5	55,304	6	48,808	5
General and administrative expenses	33,650	7	31,939	6	68,789	7	65,463	6
Research and development expenses	49,845	11	36,964	7	87,077	9	77,408	7
Expected credit loss (gain)	<u>4</u>	<u>-</u>	<u>80</u>	<u>-</u>	<u>(9,062)</u>	<u>(1)</u>	<u>8,418</u>	<u>1</u>
Total operating expenses	<u>113,655</u>	<u>24</u>	<u>93,638</u>	<u>18</u>	<u>202,108</u>	<u>21</u>	<u>200,097</u>	<u>19</u>
INCOME FROM OPERATIONS	<u>44,632</u>	<u>10</u>	<u>43,262</u>	<u>9</u>	<u>131,843</u>	<u>13</u>	<u>99,462</u>	<u>9</u>
NON-OPERATING INCOME AND EXPENSES								
Interest income (Note 22)	1,360	-	1,277	-	1,579	-	1,365	-
Other income (Notes 22 and 25)	3,789	1	4,732	1	3,980	-	5,144	-
Other gains and losses (Note 22)	<u>(4,296)</u>	<u>(1)</u>	<u>(26,263)</u>	<u>(5)</u>	<u>(4,174)</u>	<u>-</u>	<u>(1,720)</u>	<u>-</u>
Finance costs (Note 22)	<u>(804)</u>	<u>-</u>	<u>(851)</u>	<u>-</u>	<u>(1,633)</u>	<u>-</u>	<u>(1,731)</u>	<u>-</u>
Total non-operating income and expenses	<u>49</u>	<u>-</u>	<u>(21,105)</u>	<u>(4)</u>	<u>(248)</u>	<u>-</u>	<u>3,058</u>	<u>-</u>
INCOME BEFORE INCOME TAX	44,681	10	22,157	5	131,595	13	102,520	9
INCOME TAX BENEFIT (EXPENSE)								
(Notes 4 and 23)	<u>(7,835)</u>	<u>(2)</u>	<u>6,603</u>	<u>1</u>	<u>(13,379)</u>	<u>(1)</u>	<u>(11,772)</u>	<u>(1)</u>
NET INCOME	<u>36,846</u>	<u>8</u>	<u>28,760</u>	<u>6</u>	<u>118,216</u>	<u>12</u>	<u>90,748</u>	<u>8</u>

(Continued)

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended June 30				For the Six Months Ended June 30			
	2026		2025		2026		2025	
	Amount	%	Amount	%	Amount	%	Amount	%
OTHER COMPREHENSIVE INCOME								
(LOSS) (Note 20)								
Items that may be reclassified subsequently to								
profit or loss:								
Exchange differences on translation of the								
financial statements of foreign								
operations	\$ 73	-	(\$ 4,434)	(1)	\$ 956	-	(\$ 3,933)	-
TOTAL COMPREHENSIVE INCOME FOR								
THE PERIOD	<u>\$ 36,919</u>	<u>8</u>	<u>\$ 24,326</u>	<u>5</u>	<u>\$ 119,172</u>	<u>12</u>	<u>\$ 86,815</u>	<u>8</u>
NET INCOME ATTRIBUTABLE TO :								
Shareholders of the parent	\$ 36,780	8	\$ 28,651	6	\$ 118,055	12	\$ 90,678	8
Non-controlling interests	<u>66</u>	<u>-</u>	<u>109</u>	<u>-</u>	<u>161</u>	<u>-</u>	<u>70</u>	<u>-</u>
	<u>\$ 36,846</u>	<u>8</u>	<u>\$ 28,760</u>	<u>6</u>	<u>\$ 118,216</u>	<u>12</u>	<u>\$ 90,748</u>	<u>8</u>
TOTAL COMPREHENSIVE INCOME								
ATTRIBUTABLE TO :								
Shareholders of the parent	\$ 36,848	8	\$ 24,293	5	\$ 118,986	12	\$ 86,811	8
Non-controlling interests	<u>71</u>	<u>-</u>	<u>33</u>	<u>-</u>	<u>186</u>	<u>-</u>	<u>4</u>	<u>-</u>
	<u>\$ 36,919</u>	<u>8</u>	<u>\$ 24,326</u>	<u>5</u>	<u>\$ 119,172</u>	<u>12</u>	<u>\$ 86,815</u>	<u>8</u>
EARNINGS PER SHARE (Note 24)								
Basic	<u>\$ 0.37</u>		<u>\$ 0.29</u>		<u>\$ 1.18</u>		<u>\$ 0.91</u>	
Diluted	<u>\$ 0.37</u>		<u>\$ 0.29</u>		<u>\$ 1.17</u>		<u>\$ 0.90</u>	

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 7, 2026)

(Concluded)

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY****(In Thousands of New Taiwan Dollars)**

	Equity Attributable to Shareholders of the Parent								
	Share Capital			Retained Earnings		Other Equity			
	Shares				Unappropriated	Exchange			
	(In thousands)	Amount	Capital Surplus	Legal Reserve	Earnings	Differences	on	Non-controlling	
						Translation of	Foreign	Interests	Total Equity
						Operations	Total		
BALANCE ON JANUARY 1, 2025	99,950	\$ 999,502	\$ 68,368	\$ 528,094	\$ 215,963	\$ 11,670	\$ 1,823,597	\$ 634	\$ 1,824,231
Appropriation of 2024 earnings									
Legal reserve	-	-	-	13,513	(13,513)	-	-	-	-
Cash dividends -\$1.2 per share	-	-	-	-	(119,940)	-	(119,940)	-	(119,940)
Net income (loss) for the six months ended									
June 30, 2025	-	-	-	-	90,678	-	90,678	70	90,748
Other comprehensive income (loss) for the six									
months ended June 30, 2025, net of Income tax	-	-	-	-	-	(3,867)	(3,867)	(66)	(3,933)
Total comprehensive income (loss) for the six									
months ended June 30, 2025	-	-	-	-	90,678	(3,867)	86,811	4	86,815
BALANCE ON JUNE 30, 2025	99,950	\$ 999,502	\$ 68,368	\$ 541,607	\$ 173,188	\$ 7,803	\$ 1,790,468	\$ 638	\$ 1,791,106
BALANCE ON JANUARY 1, 2026	99,950	\$ 999,502	\$ 68,368	\$ 541,607	\$ 249,627	\$ 11,612	\$ 1,869,716	\$ 774	\$ 1,870,490
Appropriation of 2025 earnings									
Legal reserve	-	-	-	16,712	(16,712)	-	-	-	-
Cash dividends -\$1.3 per share	-	-	-	-	(129,935)	-	(129,935)	-	(129,935)
Net income for the six months ended									
June 30, 2026	-	-	-	-	118,055	-	118,055	161	118,216
Other comprehensive income (loss) for the six									
months ended June 30, 2026, net of Income tax	-	-	-	-	-	931	931	25	956
Total comprehensive income (loss) for the six									
months ended June 30, 2026	-	-	-	-	118,055	931	118,986	186	119,172
BALANCE ON JUNE 30, 2026	99,950	\$ 999,502	\$ 68,368	\$ 558,319	\$ 221,035	\$ 11,543	\$ 1,858,767	\$ 960	\$ 1,859,727

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 7, 2026)

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF CASH FLOWS****(In Thousands of New Taiwan Dollars)**

	For the Six Months Ended June 30	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 131,595	\$ 102,520
Adjustments for :		
Depreciation expense	25,384	27,617
Amortization expense	3,455	3,567
Expected credit (gain) loss	(9,062)	8,418
Net loss (gain) on financial assets at fair value through profit or loss	82	(19,143)
Finance costs	1,633	1,731
Interest income	(1,579)	(1,365)
Dividend income	(3,198)	(4,415)
Property, plant and equipment transferred to expenses	1,021	-
Impairment loss on non-financial assets	6,813	5,951
Unrealized foreign exchange loss	4,861	10,403
Changes in operating assets and liabilities		
Notes receivable and accounts receivable	45,220	(77,209)
Other receivables	1,536	(1,419)
Inventories	(37,626)	116,241
Other current assets	3,046	2,628
Contract liabilities	7,203	(44,481)
Notes payable	(1,521)	(8,716)
Accounts payable	(799)	(38,695)
Other payables	16,914	(4,267)
Provisions	1,124	982
Other current liabilities	(107)	(264)
Net defined benefit assets	<u>100</u>	<u>(8,806)</u>
Cash generated from operations	196,095	71,278
Interest received	1,579	1,361
Dividend received	3,198	4,415
Interest paid	(1,633)	(1,731)
Income taxes paid	<u>(9,858)</u>	<u>(6,649)</u>
Net cash generated from operating activities	<u>189,381</u>	<u>68,674</u>

(Continued)

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands of New Taiwan Dollars)

	For the Six Months Ended June 30	
	2026	2025
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment	(\$ 6,771)	(\$ 7,164)
Decrease (Increase) in refundable deposits	191	(295)
Acquisition of intangible assets	(845)	(958)
Decrease (Increase) in prepayments for business facilities	(<u>5,857</u>)	<u>2,093</u>
Net cash used in investing activities	(<u>13,282</u>)	(<u>6,324</u>)
CASH FLOWS FROM FINANCING ACTIVITIES		
Increase in short-term loans	14,398	17,580
Decrease in short-term loans	(14,398)	(17,580)
Payments of lease liabilities	(<u>4,525</u>)	(<u>4,362</u>)
Net cash used in financing activities	(<u>4,525</u>)	(<u>4,362</u>)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(<u>1,007</u>)	(<u>7,177</u>)
NET INCREASE IN CASH	170,567	50,811
CASH, BEGINNING OF THE PERIOD	<u>567,091</u>	<u>532,685</u>
CASH, END OF THE PERIOD	<u>\$ 737,658</u>	<u>\$ 583,496</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 7, 2026)

(Concluded)

APEX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

1. GENERAL INFORMATION

Apex Biotechnology Corporation (“APEX”) was incorporated on December 2, 1997, and is primarily engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business.

APEX’s shares have been listed on the Taiwan Stock Exchange (TWSE) since September 19, 2001.

The consolidated financial statements are presented in APEX’s functional currency, the New Taiwan dollar.

2. APPROVAL OF FINANCIAL STATEMENTS

The consolidated financial statements were approved and authorized for issued by the board of directors on August 7, 2026.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. Initial application of the amendments to the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) (collectively, the “IFRS Accounting Standards”) endorsed and issued into effect by the Financial Supervisory Commission (FSC)

The initial application of the IFRS Accounting Standards endorsed and issued into effect by the FSC did not have a material impact on the accounting policies of APEX and its subsidiaries (collectively as the “Company”)

- b. The IFRS Accounting Standards endorsed by the FSC for application starting from 2027

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note 1)
IFRS 19 “Subsidiaries without Public Accountability: Disclosures” (including the 2025 amendments to IFRS 19)	January 1, 2027

(Continued)

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB
Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”	January 1, 2027
Amendments to IAS 28 “Amendments to the Fair Value Option for Investments in Associates and Joint Ventures”	January 1, 2027 (Note 2)
	(Concluded)

Note 1: Taiwanese enterprises should apply IFRS 18 from January 1, 2028. They may also choose to apply IFRS 18 earlier after the FSC approves it.

Note 2: An entity must apply the consequential amendments at the same time it applies IFRS 18.

- 1) IFRS 18 “Presentation and Disclosure in Financial Statements” and consequential amendments and Amendments to IAS 28 “Amendments to the Fair Value Option for Investments in Associates and Joint Ventures”

IFRS 18 will supersede IAS 1 “Presentation of Financial Statements”. The main changes comprise:

- To classify items of income and expenses presented in the statement of profit or loss into the operating, investing, financing, income taxes and discontinued operations categories, the Company shall assess whether it has specified main business activities of investing in particular types of assets and providing financing to customers.
- The statement of profit or loss shall present totals and subtotals for operating profit or loss, profit or loss before financing and income taxes and profit or loss.
- Provides guidance to enhance the requirements of aggregation and disaggregation: The Company shall identify the assets, liabilities, equity, income, expenses and cash flows that arise from individual transactions or other events and shall classify and aggregate them into groups based on shared characteristics, so as to result in the presentation in the primary financial statements of line items that have at least one similar characteristic. The Company shall disaggregate items with dissimilar characteristics in the primary financial statements and in the notes. The Company labels items as “other” only if it cannot find a more informative label.
- Disclosures on Management-defined Performance Measures (MPMs): When in public communications outside financial statements and communicating to users of financial statements management’s view of an aspect of the financial performance of the Company as a whole, the Company shall disclose related information about its MPMs in a single note to the financial statements, including the description of such measures, calculations, reconciliations to the subtotal or total specified by IFRS Accounting Standards and the income tax and non-controlling interests effects of related reconciliation items.

At the date of initial application of IFRS 18, an entity that is a venture capital organization, mutual fund, unit trust or similar entity is permitted to change its election from measuring an investment in an associate or joint venture from the equity method to fair value through profit or loss. The amendments to IAS 28 clarify that aforementioned “similar entity” includes the entity that performs the assessments in accordance with the requirements of IFRS 18 and concludes that it has a main business activity of investing in particular types of assets. If eligible, the Company may apply the transition upon initial application.

In addition, the following consequential amendments have been made to IAS 7 “Statement of Cash

Flows”:

- The Company shall use operating profit or loss as the starting point when presenting cash flows from operating activities under the indirect method.
- Interest and dividends received by the Company shall be classified as investing activities, while interest and dividends paid shall be classified as financing activities. However, if, after assessment, the Company has a specific main operating activity, it shall determine how to classify dividends received, interest received and interest paid in the statement of cash flows by referring to how it classifies dividend income, interest income and interest expense in the statement of profit or loss. The total of each of these cash flows shall be classified in a single category in the statement of cash flows.

Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Company is continuously assessing the other impacts of the above amended standards and interpretations on the Company’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

- c. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB (Note 1)
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB
IFRS 20 “Regulatory Assets and Regulatory Liabilities”	January 1, 2029

Note 1: Unless stated otherwise, the above IFRS Accounting Standards are effective for annual reporting periods beginning on or after their respective effective dates.

As of the date the consolidated financial statements were authorized for issue, the Company is continuously assessing the impacts of the above amended standards and interpretations on the Company’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

- a. Statement of compliance

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 “Interim Financial Reporting” as endorsed and issued into effect by the FSC. The disclosed information included in these interim consolidated financial statements is less than the disclosed information required in a complete set of annual consolidated financial statements.

- b. Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value and net defined benefit assets or liabilities which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for an asset or liability.

c. Basis of consolidation

The consolidated financial statements incorporate the financial statements of APEX and the entities controlled by APEX (i.e., its subsidiaries).

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Company.

All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of APEX and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

See Notes 11 and 31 for detailed information on subsidiaries (including the percentages of ownership and main businesses).

d. Other material accounting policies

Except for the following, refer to the consolidated financial statements for the year ended December 31, 2025.

1) Retirement benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant plan amendments, settlements, or other significant one-off events.

2) Income tax expense

Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's

pre-tax income the tax rate that would be applicable to expected total annual earnings.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Company's accounting policies, management is required to make judgments, estimations, and assumptions on the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.

When developing material accounting estimates, the Company considers the possible impact of inflation, interest rate fluctuations and US reciprocal tariffs on the cash flow projections, growth rates, discount rates, profitability and other relevant material estimates. The estimates and underlying assumptions are reviewed on an ongoing basis.

For other related information refer to the statements of critical accounting judgments and key sources of estimation uncertainty to the consolidated financial statements for the year ended December 31, 2025.

6. CASH

	June 30, 2026	December 31, 2025	June 30, 2025
Cash on hand	\$ 490	\$ 400	\$ 414
Demand deposits	<u>737,168</u>	<u>566,691</u>	<u>583,082</u>
	<u>\$ 737,658</u>	<u>\$ 567,091</u>	<u>\$ 583,496</u>

7. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Financial assets at FVTPL -current</u>			
Financial assets mandatorily classified as at FVTPL			
Non-derivative financial assets			
Domestic emerging market shares	\$ 53,356	\$ 61,164	\$ 53,658
Domestic and foreign unlisted shares	<u>23,837</u>	<u>16,111</u>	<u>37,584</u>
	<u>\$ 77,193</u>	<u>\$ 77,275</u>	<u>\$ 91,242</u>

8. FINANCIAL ASSETS AT AMORTIZED COST

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Non-current</u>			
Domestic investments			
Time deposits with original maturities of more than 3 months	\$ 6,200	\$ 6,200	\$ 6,200

- a. The ranges of interest rates for time deposits with original maturities of more than 3 months were all 1.750% per annum as of June 30, 2026, December 31, 2025, and June 30, 2025.
- b. Refer to Note 29 for information relating to investments in financial assets at amortized cost pledged as security.

9. NOTES RECEIVABLE, ACCOUNTS RECEIVABLE AND OTHER RECEIVABLES

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Notes receivable</u>			
Notes receivable - operating	\$ 4,654	\$ 6,851	\$ 5,925
<u>Accounts receivable</u>			
At amortized cost			
Gross carrying amount	396,655	442,147	412,006
Less: Allowance for impairment loss	(2,178)	(11,199)	(9,920)
	<u>394,477</u>	<u>430,948</u>	<u>402,086</u>
	<u>\$ 399,131</u>	<u>\$ 437,799</u>	<u>\$ 408,011</u>
<u>Other receivables</u>			
Tax receivable	\$ 7,937	\$ 8,083	\$ 6,910
Others	<u>333</u>	<u>1,723</u>	<u>2,593</u>
	<u>\$ 8,270</u>	<u>\$ 9,806</u>	<u>\$ 9,503</u>

Accounts receivable

The average credit period on sales of goods ranges from 15 to 150 days, and accounts receivable are non-interest bearing. To enhance the credit risk management, new customers are initially granted small credit limits. Once a stable trading relationship and a certain sales volume are established, the Company engages professional credit rating agencies to determine the credit limit based on the relevant reports. This is complemented by ongoing monitoring procedures to ensure timely and appropriate actions are taken to recover overdue receivables. Furthermore, the Company reviews the recoverable amount of each receivable at the reporting date to ensure that the adequate impairment losses are recognized for uncollectible accounts.

The Company measures the loss allowance for accounts receivable at an amount equal to lifetime ECLs. The expected credit losses on accounts receivable are estimated using a provision matrix prepared by reference to the past default experience of the customer, the customer's current financial position, economic condition of the industry in which the customer operates, as well as the industry outlook. The Company uses different provision matrixes based on customer segments by credit rating, transaction type, and determines the expected credit loss rate by reference to past due days of accounts receivable.

The Company writes off an account receivable when there is evidence indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. For accounts receivable that have been written off, the Company continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of accounts receivable based on the Company's provision matrix.

June 30, 2026

		1 to 30 Days	31 to 90 Days	91 to 180 Days Past	Over 181 Days Past	
	Not Past Due	Past Due	Past Due	Due	Due	Total
Expected credit loss rate	0.01%	0.02%	12.39%	44.88%	100%	
Gross carrying amount	\$ 320,317	\$ 73,678	\$ 331	\$ 430	\$ 1,899	\$ 396,655
Loss allowance (Lifetime ECLs)	(33)	(12)	(41)	(193)	(1,899)	(2,178)
Amortized cost	<u>\$ 320,284</u>	<u>\$ 73,666</u>	<u>\$ 290</u>	<u>\$ 237</u>	<u>\$ -</u>	<u>\$ 394,477</u>

December 31, 2025

		1 to 30 Days	31 to 90 Days	91 to 180 Days Past	Over 181 Days Past	
	Not Past Due	Past Due	Past Due	Due	Due	Total
Expected credit loss rate	0.01%	0.07%	0.22%	94.24%	100%	
Gross carrying amount	\$ 303,037	\$ 77,681	\$ 50,433	\$ 139	\$ 10,857	\$ 442,147
Loss allowance (Lifetime ECLs)	(42)	(57)	(112)	(131)	(10,857)	(11,199)
Amortized cost	<u>\$ 302,995</u>	<u>\$ 77,624</u>	<u>\$ 50,321</u>	<u>\$ 8</u>	<u>\$ -</u>	<u>\$ 430,948</u>

June 30, 2025

				91 to 180	Over 181	
		1 to 30 Days	31 to 90 Days	Days Past	Days Past	
	Not Past Due	Past Due	Past Due	Due	Due	Total
Expected credit loss rate	0.00%	0.01%	32.16%	94.35%	100%	
Gross carrying amount	\$ 298,398	\$ 103,085	\$ 171	\$ 9,003	\$ 1,349	\$ 412,006
Loss allowance (Lifetime ECLs)	(13)	(9)	(55)	(8,494)	(1,349)	(9,920)
Amortized cost	<u>\$ 298,385</u>	<u>\$ 103,076</u>	<u>\$ 116</u>	<u>\$ 509</u>	<u>\$ -</u>	<u>\$ 402,086</u>

The movements of the loss allowance of accounts receivable were as follows:

	For the Six Months Ended	
	June 30	
	2026	2025
Balance on January 1	\$ 11,199	\$ 1,870
Add : Net remeasurement of loss allowance	-	8,418
Less : Net remeasurement of loss allowance	(9,062)	-
Less : Amounts written off	-	(182)
Foreign exchange gains and losses	(42)	(186)
Balance on June 30	<u>\$ 2,178</u>	<u>\$ 9,920</u>

10. INVENTORIES

	June 30, 2026	December 31, 2025	June 30, 2025
Finished goods and merchandise	\$ 105,864	\$ 144,399	\$ 105,842
Work in progress	269,826	216,982	237,117
Raw materials	<u>216,957</u>	<u>200,453</u>	<u>197,340</u>
	<u>\$ 592,647</u>	<u>\$ 561,834</u>	<u>\$ 540,299</u>

The cost of inventories recognized as cost of goods sold for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025 were NT\$312,366 thousand, NT\$373,048 thousand, NT\$656,425 thousand and NT\$769,142 thousand, respectively. The cost of goods sold included inventory write-downs were NT\$3,443 thousand, NT\$3,031 thousand, NT\$6,813 thousand and NT\$5,951 thousand, respectively.

11. SUBSIDIARIES

The consolidated financial statements include subsidiaries which are as follows:

Investor	Investee	Nature of Activities	Proportion of Ownership (%)			Remark
			June 30, 2026	December 31, 2025	June 30, 2025	
APEX	Omnis Health LLC	Engaged in the import and export of medical devices	99%	99%	99%	-
	Apex Biotechnology (Suzhou) Corporation	Engaged in the import and export of medical devices	96%	96%	96%	1

Note 1 : The subsidiary included in the consolidated financial statements is non-significant, and its financial statements has not been reviewed.

12. PROPERTY, PLANT AND EQUIPMENT

	Land	Buildings	Machinery Equipment	Testing Equipment	Transportation Equipment	Office Equipment	Miscellaneous Equipment	Equipment under Acceptance	Total
<u>Cost</u>									
Balance on January 1, 2026	\$261,675	\$605,024	\$517,206	\$ 54,982	\$ 4,218	\$ 21,412	\$207,813	\$ 10,452	\$ 1,682,782
Additions	-	270	1,285	-	-	115	540	5,071	7,281
Disposals	-	-	(2,287)	-	-	(27)	(95)	(1,021)	(3,430)
Reclassification	-	-	3,740	-	-	-	385	(4,125)	-
Effects of exchange rate changes	-	-	20	-	-	12	35	-	67
Balance on June 30, 2026	<u>\$261,675</u>	<u>\$605,294</u>	<u>\$519,964</u>	<u>\$ 54,982</u>	<u>\$ 4,218</u>	<u>\$ 21,512</u>	<u>\$208,678</u>	<u>\$ 10,377</u>	<u>\$1,686,700</u>
<u>Accumulated depreciation</u>									
Balance on January 1, 2026	\$ -	\$397,531	\$478,325	\$ 39,296	\$ 2,279	\$ 18,088	\$195,060	\$ -	\$ 1,130,579
Depreciation expenses	-	8,006	6,482	2,368	348	636	2,670	-	20,510
Disposals	-	-	(2,287)	-	-	(27)	(95)	-	(2,409)
Effects of exchange rate changes	-	-	18	-	-	9	33	-	60
Balance on June 30, 2026	<u>\$ -</u>	<u>\$405,537</u>	<u>\$482,538</u>	<u>\$ 41,664</u>	<u>\$ 2,627</u>	<u>\$ 18,706</u>	<u>\$197,668</u>	<u>\$ -</u>	<u>\$1,148,740</u>
Carrying amount on June 30, 2026	<u>\$261,675</u>	<u>\$199,757</u>	<u>\$ 37,426</u>	<u>\$ 13,318</u>	<u>\$ 1,591</u>	<u>\$ 2,806</u>	<u>\$ 11,010</u>	<u>\$ 10,377</u>	<u>\$537,960</u>
Carrying amount on December 31, 2025 and									
January 1, 2026	<u>\$261,675</u>	<u>\$207,493</u>	<u>\$ 38,881</u>	<u>\$ 15,686</u>	<u>\$ 1,939</u>	<u>\$ 3,324</u>	<u>\$ 12,753</u>	<u>\$ 10,452</u>	<u>\$ 552,203</u>

(Continued)

			Machinery	Testing	Transportation	Office	Miscellaneous	Equipment under	
	Land	Buildings	Equipment	Equipment	Equipment	Equipment	Equipment	Acceptance	Total
<u>Cost</u>									
Balance on January 1, 2025	\$261,675	\$605,024	\$509,706	\$ 52,054	\$ 4,218	\$ 22,158	\$205,884	\$ 12,467	\$ 1,673,186
Additions	-	-	1,537	476	-	658	1,139	3,391	7,201
Disposals	-	-	(115)	-	-	-	(41)	-	(156)
Reclassification	-	-	3,322	-	-	-	123	(3,445)	-
Effects of exchange rate changes	-	-	(164)	-	-	(40)	(76)	-	(280)
Balance on June 30, 2025	<u>\$261,675</u>	<u>\$605,024</u>	<u>\$514,286</u>	<u>\$ 52,530</u>	<u>\$ 4,218</u>	<u>\$ 22,776</u>	<u>\$207,029</u>	<u>\$ 12,413</u>	<u>\$1,679,951</u>
<u>Accumulated depreciation</u>									
Balance on January 1, 2025	\$ -	\$379,972	\$466,127	\$ 33,965	\$ 1,583	\$ 18,020	\$192,335	\$ -	\$1,092,002
Depreciation expenses	-	9,335	6,679	2,651	348	758	2,986	-	22,757
Disposals	-	-	(115)	-	-	-	(41)	-	(156)
Effects of exchange rate changes	-	-	(110)	-	-	(31)	(67)	-	(208)
Balance on June 30, 2025	<u>\$ -</u>	<u>\$389,307</u>	<u>\$472,581</u>	<u>\$ 36,616</u>	<u>\$ 1,931</u>	<u>\$ 18,747</u>	<u>\$195,213</u>	<u>\$ -</u>	<u>\$1,114,395</u>
Carrying amount on June 30, 2025	<u>\$261,675</u>	<u>\$215,717</u>	<u>\$ 41,705</u>	<u>\$ 15,914</u>	<u>\$ 2,287</u>	<u>\$ 4,029</u>	<u>\$ 11,816</u>	<u>\$ 12,413</u>	<u>\$ 565,556</u>

(Concluded)

The Company's property, plant and equipment are all for self-use.

No impairment loss recognized or reversed for the six months ended June 30, 2026 and 2025.

The above items of property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives as follows:

Buildings

Main buildings	21-47 years
Electronic equipment	5-15 years
Machinery equipment	5-10 years
Testing equipment	3-10 years
Transportation equipment	5-10 years
Office equipment	3-6 years
Miscellaneous equipment	2-20 years

13. LEASE ARRANGEMENTS

a. Right-of-use assets

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Carrying amount</u>			
Land	\$ 91,888	\$ 93,690	\$ 95,491
Buildings	2,320	3,355	5,229
Transportation equipment	1,526	2,035	2,543
Office equipment	<u>1,132</u>	<u>1,360</u>	<u>1,627</u>
	<u>\$ 96,866</u>	<u>\$ 100,440</u>	<u>\$ 104,890</u>

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2026	2025	2026	2025
Additions to right-of-use assets			<u>\$ 1,257</u>	<u>\$ -</u>
Depreciation charge for right-of-use assets				
Land	\$ 900	\$ 901	\$ 1,801	\$ 1,802
Buildings	1,149	1,106	2,292	2,281
Transportation equipment	254	255	509	509
Office equipment	<u>138</u>	<u>134</u>	<u>272</u>	<u>268</u>
	<u>\$ 2,441</u>	<u>\$ 2,396</u>	<u>\$ 4,874</u>	<u>\$ 4,860</u>

Except for the aforementioned additions and recognized depreciation, the Company did not have significant sublease or impairment of right-of-use assets during the six months ended June 30, 2026 and 2025.

b. Lease liabilities

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Carrying amount</u>			
Current	<u>\$ 5,760</u>	<u>\$ 7,692</u>	<u>\$ 8,485</u>
Non-current	<u>\$ 100,686</u>	<u>\$ 101,982</u>	<u>\$ 105,207</u>

Range of discount rate for lease liabilities was as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Land	2.93%	2.93%	2.93%
Buildings	0.86%-3.60%	0.86%-3.45%	0.86%-3.45%
Transportation equipment	5.78%	5.78%	5.78%
Office equipment	5.78%-5.91%	5.78%	5.78%

c. Material leasing activities and terms

The Company leases land and buildings for the use of plants and offices with lease terms of 2 ~ 33 years.

d. Other lease information

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Expenses relating to short-term leases	\$ 267	\$ 430	\$ 577	\$ 808
Total cash outflow for leases			(\$ 6,723)	(\$ 6,887)

The Company leases certain office buildings and equipment which qualify as short-term leases. The Company has elected to apply the recognition exemption and thus, did not recognize right-of-use assets and lease liabilities for these lease

14. INTANGIBLE ASSETS

	Software	Trademarks	Patents	Customer Relationship	Total
<u>Cost</u>					
Balance on January 1, 2026	\$ 19,295	\$ 155,582	\$ 33,632	\$ 101,205	\$ 309,714
Additions	-	-	845	-	845
Effects of exchange rate changes	-	2,016	-	1,352	3,368
Balance on June 30, 2026	<u>\$ 19,295</u>	<u>\$ 157,598</u>	<u>\$ 34,477</u>	<u>\$ 102,557</u>	<u>\$ 313,927</u>
<u>Accumulated amortization</u>					
Balance on January 1, 2026	\$ 16,373	\$ 138,800	\$ 17,626	\$ 101,205	\$ 274,004
Amortization expenses	393	2,113	949	-	3,455
Effects of exchange rate changes	-	1,820	-	1,352	3,172
Balance on June 30, 2026	<u>\$ 16,766</u>	<u>\$ 142,733</u>	<u>\$ 18,575</u>	<u>\$ 102,557</u>	<u>\$ 280,631</u>
Carrying amount on June 30, 2026	<u>\$ 2,529</u>	<u>\$ 14,865</u>	<u>\$ 15,902</u>	<u>\$ -</u>	<u>\$ 33,296</u>
Carrying amounts on December 31,					
2025 and January 1, 2026	<u>\$ 2,922</u>	<u>\$ 16,782</u>	<u>\$ 16,006</u>	<u>\$ -</u>	<u>\$ 35,710</u>

	Software	Trademarks	Patents	Customer Relationship	Total
Cost					
Balance on January 1, 2025	\$ 19,295	\$ 162,085	\$ 29,633	\$ 105,568	\$ 316,581
Additions	-	-	958	-	958
Effects of exchange rate changes	-	(16,724)	-	(11,222)	(27,946)
Balance on June 30, 2025	<u>\$ 19,295</u>	<u>\$ 145,361</u>	<u>\$ 30,591</u>	<u>\$ 94,346</u>	<u>\$ 289,593</u>
<u>Accumulated amortization</u>					
Balance on January 1, 2025	\$ 15,281	\$ 140,241	\$ 15,895	\$ 105,568	\$ 276,985
Amortization expenses	570	2,136	861	-	3,567
Effects of exchange rate changes	-	(14,696)	-	(11,222)	(25,918)
Balance on June 30, 2025	<u>\$ 15,851</u>	<u>\$ 127,681</u>	<u>\$ 16,756</u>	<u>\$ 94,346</u>	<u>\$ 254,634</u>
Carrying amount on June 30, 2025	<u>\$ 3,444</u>	<u>\$ 17,680</u>	<u>\$ 13,835</u>	<u>\$ -</u>	<u>\$ 34,959</u>

Except for addition and amortization recognized, the Company did not have significant disposal or impairment of intangible assets during the six months ended June 30, 2026 and 2025.

Intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Trademarks	7-12 years
Patents	10-26 years
Software	3-10 years

15. OTHER CURRENT ASSETS

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Current</u>			
Prepayments (Note)	\$ 15,415	\$ 18,816	\$ 17,304
Others	<u>1,332</u>	<u>977</u>	<u>1,138</u>
	<u>\$ 16,747</u>	<u>\$ 19,793</u>	<u>\$ 18,442</u>

Note : The prepayments mainly consist of prepaid patents, trademarks, repairs and maintenance, and insurance premiums.

16. NOTES PAYABLE AND ACCOUNTS PAYABLE

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Notes payable</u>			
Operating	\$ <u>37,666</u>	\$ <u>39,187</u>	\$ <u>34,491</u>
<u>Accounts payable</u>			
Operating	\$ <u>192,298</u>	\$ <u>192,508</u>	\$ <u>154,745</u>

The average credit period on purchases of certain goods ranges from 30 to 90 days. The Company has financial risk management policies in place to ensure that all payables are settled within the pre-agreed credit terms.

17. OTHER LIABILITIES

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Current</u>			
Other payables			
Payables for salaries and bonuses	\$ 48,982	\$ 61,677	\$ 47,388
Payables for employees' compensation and remuneration of directors	29,631	18,753	20,532
Payables for research expenses	12,225	-	-
Payables for purchases of equipment	2,070	1,560	1,519
Others (Note)	<u>68,823</u>	<u>62,318</u>	<u>57,921</u>
	\$ <u>161,731</u>	\$ <u>144,308</u>	\$ <u>127,360</u>
	June 30, 2026	December 31, 2025	June 30, 2025
<u>Other liabilities</u>			
Receipts under custody	\$ <u>2,955</u>	\$ <u>3,062</u>	\$ <u>2,935</u>

Note: Other payables mainly consist of consumables, utilities, and cleaning fees, incurred by the Company arising from operations.

18. PROVISIONS

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Current</u>			
Employee benefits (Note)	\$ <u>13,304</u>	\$ <u>12,180</u>	\$ <u>13,107</u>

Note : The provision for employee benefits represents vested service leave entitlements accrued.

19. RETIREMENT BENEFIT PLANS

For the three months ended and six months ended June 30, 2026 and 2025, the pension expenses of defined benefit plans were NT\$50 thousand, NT\$126 thousand, NT\$100 thousand and NT\$253 thousand, respectively, and these were calculated based on the pension cost rate determined by the actuarial calculation on December 31, 2025 and 2024, respectively.

20. EQUITY

a. Ordinary shares

	June 30, 2026	December 31, 2025	June 30, 2025
Authorized shares (in thousands)	<u>200,000</u>	<u>200,000</u>	<u>200,000</u>
Authorized capital	<u>\$ 2,000,000</u>	<u>\$ 2,000,000</u>	<u>\$ 2,000,000</u>
Issued and paid shares (in thousands)	<u>99,950</u>	<u>99,950</u>	<u>99,950</u>
Issued capital	<u>\$ 999,502</u>	<u>\$ 999,502</u>	<u>\$ 999,502</u>

A holder of issued common shares with par value of NT\$10 per share is entitled to vote and to receive dividends.

b. Capital surplus

	June 30, 2026	December 31, 2025	June 30, 2025
May be used to offset a deficit, distributed as cash dividends, or transferred to share capital (Note)			
Conversion of convertible bonds	\$ 26,570	\$ 26,570	\$ 26,570
Treasury share transactions	1,592	1,592	1,592
Amount transferred to capital surplus from stock options upon bond redemption	<u>40,206</u>	<u>40,206</u>	<u>40,206</u>
	<u>\$ 68,368</u>	<u>\$ 68,368</u>	<u>\$ 68,368</u>

Note : Such capital surplus may be used to offset a deficit; in addition, when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's paid-in capital and once a year).

c. Retained earnings and dividends policy

Under the dividends policy as set forth in APEX's Articles of Incorporation, where the Company made a profit in a fiscal year, the profit shall be first utilized for paying taxes, offsetting losses of previous

years, setting aside as legal reserve 10% of the remaining profit until the amount of the legal reserve equals the amount of APEX's paid-in capital, setting aside or reverse special reserve in accordance with the laws or the regulations of the competent authority, and then any remaining profit together with any undistributed retained earnings shall be used by the board of directors as the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders. For the all or part of the distribution of dividends and bonuses, if the distribution is in cash, the board of directors shall be authorized to resolve the proposal by the vote of at least half of the directors present, provided the number of directors present shall be at least two-thirds of the entire board of directors, and report the distribution to the shareholders' meeting.

For the policies on the distribution of compensation of employees and remuneration of directors, refer to compensation of employees and remuneration of directors in Note 22(g).

The dividend policy shall be conditioned by the business expansion and cash flow need of the company in the futures, the shareholders interest, balance of dividend payment and long-term financial planning shall also be considered. The total dividends amount shall be no less than fifty percent (50%) of the total accumulative distributed profit of the year, amount which the cash dividend ratio shall be no less than twenty percent (20%) of the total dividends.

An appropriation of earnings to a legal reserve shall be made until the legal reserve equals APEX's paid-in capital. The legal reserve may be used to offset deficits. If APEX has no deficit and the legal reserve has exceeded 25% of APEX's paid-in capital, the excess may be transferred to capital or distributed in cash.

The appropriations of earnings for 2025 and 2024 were as follows:

	Appropriation of Earnings	
	For the Year Ended	
	December 31	
	2025	2024
Legal reserve	\$ <u>16,712</u>	\$ <u>13,513</u>
Cash dividends	\$ <u>129,935</u>	\$ <u>119,940</u>
Cash dividends per share (NT\$)	\$ 1.3	\$ 1.2

The above 2025 and 2024 appropriations for cash dividends had been resolved by the board of directors on March 13, 2026 and February 25, 2025, respectively; the other proposed appropriations were resolved by the shareholders in their meeting on May 22, 2026 and May 23, 2025, respectively.

d. Other equity items

Exchange differences on the translation of the financial statements of foreign operations

	For the Six Months Ended June 30	
	2026	2025
Balance on January 1	\$ 10,612	\$ 11,670
Recognized for the period		
Exchange differences on the translation of the financial statements of foreign operations	<u>931</u>	<u>(3,867)</u>
Balance on June 30	<u>\$ 11,543</u>	<u>\$ 7,803</u>

e. Non-controlling interests

	For the Six Months Ended June 30	
	2026	2025
Balance on January 1	\$ 774	\$ 634
Share in profit for the period	161	70
Other comprehensive income (loss) during the period		
Exchange differences on translating the financial statements of foreign entities	<u>25</u>	<u>(66)</u>
Balance on June 30	<u>\$ 960</u>	<u>\$ 638</u>

21. REVENUE

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2026	2025	2026	2025
Revenue from contracts with customers				
Revenue from the sale of goods	\$ 470,081	\$ 508,748	\$ 988,839	\$ 1,066,628
Other operating revenue	<u>572</u>	<u>1,200</u>	<u>1,537</u>	<u>2,073</u>
	<u>\$ 470,653</u>	<u>\$ 509,948</u>	<u>\$ 990,376</u>	<u>\$ 1,068,701</u>

a. Contract information

Revenue from the sale of goods

The Company estimates the sales discounts using the most likely amount based on historical experience. However, considering that discounts offered by major competitors are more favorable than the initial estimate, the Company determines the amount of revenue to be recognized based on these more competitive discount rates. Other products are sold at fixed prices stipulated in the contracts.

b. Contract balances

	June 30, 2026	December 31, 2025	June 30, 2025	January 1, 2025
Accounts receivable (Note 9)	\$ 394,477	\$ 430,948	\$ 402,086	\$ 340,982
Contract liabilities				
Sale of goods	\$ 14,436	\$ 7,233	\$ 13,797	\$ 58,278

The changes in the contract liability balances primarily result from the timing difference between the satisfaction of the performance obligations and the respective customer's payment.

Revenue in the current year that was recognized from the contract liability balance on the beginning of the year and from the performance obligations satisfied in the previous periods was summarized as follows:

	For the Six Months Ended June 30	
	2026	2025
<u>From contract liabilities at the start of the year</u>		
Sale of goods	\$ 5,312	\$ 53,294

c. Disaggregation of revenue

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2026	2025	2026	2025
USA	\$ 199,317	\$ 251,427	\$ 402,319	\$ 541,246
Italy	144,796	143,360	328,159	295,270
Austria	73,255	38,649	123,086	105,636
Taiwan	19,950	19,305	39,719	36,406
Others	<u>33,335</u>	<u>57,207</u>	<u>97,093</u>	<u>90,143</u>
	<u>\$ 470,653</u>	<u>\$ 509,948</u>	<u>\$ 990,376</u>	<u>\$ 1,068,701</u>

22. NET PROFIT FROM CONTINUING OPERATIONS

a. Interest income

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Bank deposits	\$ 1,360	\$ 1,277	\$ 1,579	\$ 1,365

b. Other income

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Dividend income	\$ 3,198	\$ 4,415	\$ 3,198	\$ 4,415
Rental income	150	156	300	385
Grant income (Note 25)	130	-	130	119
Others	311	161	352	225
	<u>\$ 3,789</u>	<u>\$ 4,732</u>	<u>\$ 3,980</u>	<u>\$ 5,144</u>

c. Other gains and losses

	For the Three Months Ended		For the Nine Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Net foreign exchange loss	(\$ 7,528)	(\$ 49,401)	(\$ 4,092)	(\$ 20,906)
Fair value changes of financial assets and financial liabilities				
Financial assets mandatorily classified as at FVTPL	3,232	(23,095)	(82)	19,143
Others	-	43	-	43
	<u>(\$ 4,296)</u>	<u>(\$ 26,263)</u>	<u>(\$ 4,174)</u>	<u>(\$ 1,720)</u>

d. Finance costs

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Interest on lease liabilities	\$ 804	\$ 851	\$ 1,621	\$ 1,717
Interest on bank loans	<u>-</u>	<u>-</u>	<u>12</u>	<u>14</u>
	<u>\$ 804</u>	<u>\$ 851</u>	<u>\$ 1,633</u>	<u>\$ 1,731</u>

e. Depreciation and amortization

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
An analysis of depreciation by function				
Operating costs	\$ 8,372	\$ 9,113	\$ 16,855	\$ 18,579
Operating expenses	<u>4,155</u>	<u>4,484</u>	<u>8,529</u>	<u>9,038</u>
	<u>\$ 12,527</u>	<u>\$ 13,597</u>	<u>\$ 25,384</u>	<u>\$ 27,617</u>

An analysis of amortization by function				
Operating costs	\$ 115	\$ 150	\$ 251	\$ 314
Selling and marketing expenses	69	76	142	155
General and administrative expenses	1,006	993	2,023	2,056
Research and development expenses	<u>514</u>	<u>514</u>	<u>1,039</u>	<u>1,042</u>
	<u>\$ 1,704</u>	<u>\$ 1,733</u>	<u>\$ 3,455</u>	<u>\$ 3,567</u>

f. Employee benefits expense

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Short-term benefits	\$ 136,277	\$ 129,719	\$ 278,525	\$ 269,100
Post-employment benefits				
Defined contribution plan	4,069	4,049	8,115	8,037
Defined benefit plans (Note 19)	<u>50</u>	<u>126</u>	<u>100</u>	<u>253</u>
Total employee benefits expense	<u>\$ 140,396</u>	<u>\$ 133,894</u>	<u>\$ 286,740</u>	<u>\$ 277,390</u>

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
An analysis of employee benefits expense by function				
Operating costs	\$ 81,708	\$ 77,016	\$ 160,493	\$ 160,711
Operating expenses	<u>58,688</u>	<u>56,878</u>	<u>121,247</u>	<u>116,679</u>
	<u>\$ 140,396</u>	<u>\$ 133,894</u>	<u>\$ 286,740</u>	<u>\$ 277,390</u>

g. Compensation of employees and remuneration of directors

According to the APEX's Articles of Incorporation, APEX accrues compensation of employees and remuneration of directors at rates of no less than 3% and no higher than 1%, respectively, of net profit before income tax, compensation of employees, and remuneration of directors. In accordance with the amendments to the Securities and Exchange Act in August 2024, the shareholders of the Company resolved the amendments to the Company's Articles at their 2025 regular meeting. The amendments explicitly stipulate the allocation of no less than 50% of the compensation of employees as compensation distributions for non-executive employees. The compensation of employees (including non-executive employees) and the remuneration of directors for the three months and six months ended June 30, 2026 and 2025, are as follows:

Accrual rate

	For the Six Months Ended	
	June 30	
	2026	2025
Compensation of employees	8%	7%
Remuneration of directors	1%	1%

Amount

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Compensation of employees	\$ 3,605	\$ 721	\$ 11,523	\$ 7,772
Remuneration of directors	\$ 450	\$ 103	\$ 1,440	\$ 1,110

If there is a change in the amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The appropriations of compensation of employees and remuneration of directors for 2025 and 2024 that were resolved by the board of directors on March 13, 2026 and February 25, 2025, respectively, are as shown below:

	For the Year Ended December 31			
	2025		2024	
	Cash	Shares	Cash	Shares
Compensation of employees	\$ 16,669	\$ -	\$ 11,650	\$ -
Remuneration of directors	2,084	-	1,664	-

There is no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the consolidated financial statements for the years ended December 31, 2025 and 2024.

Information on the compensation of employees and remuneration of directors resolved by the APEX's board of directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

h. Gains or losses on foreign currency exchange

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Foreign exchange gains	\$ 3,476	(\$ 810)	\$ 10,752	\$ 30,391
Foreign exchange losses	(11,004)	(48,591)	(14,844)	(51,297)
	(\$ 7,528)	(\$ 49,401)	(\$ 4,092)	(\$ 20,906)

23. INCOME TAXES

a. Income tax recognized in profit or loss

Major components of income tax expense (benefit) are as follows:

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2026	2025	2026	2025
Current tax				
In respect of the current period	\$ 8,319	\$ 1,105	\$ 23,217	\$ 18,129
Adjustments for prior periods	<u>-</u>	<u>(10,077)</u>	<u>(8,415)</u>	<u>(10,077)</u>
	<u>8,319</u>	<u>(8,972)</u>	<u>14,802</u>	<u>8,052</u>
Deferred tax				
In respect of the current period	(483)	2,360	(1,422)	3,711
Effects of exchange rate changes	<u>(1)</u>	<u>9</u>	<u>(1)</u>	<u>9</u>
	<u>(484)</u>	<u>2,369</u>	<u>(1,423)</u>	<u>3,720</u>
Income tax expense (benefit) recognized in profit or loss	<u>\$ 7,835</u>	<u>(\$ 6,603)</u>	<u>\$ 13,379</u>	<u>\$ 11,772</u>

b. Income tax assessments

The income tax returns through 2024 have been assessed by the tax authorities.

24. EARNINGS PER SHARE

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2026	2025	2026	2025
Basic earnings per share	<u>\$ 0.37</u>	<u>\$ 0.29</u>	<u>\$ 1.18</u>	<u>\$ 0.91</u>
Diluted earnings per share	<u>\$ 0.37</u>	<u>\$ 0.29</u>	<u>\$ 1.17</u>	<u>\$ 0.90</u>

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share were as follows:

Net Income for the Period

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Income for the period attributable to shareholders of the parent used in the computation of basic earnings per share and diluted earnings per share	\$ 36,780	\$ 28,651	\$ 118,055	\$ 90,678

Number of shares (in thousands)

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Weighted average number of ordinary shares used in the computation of basic earnings per share	99,950	99,950	99,950	99,950
Effect of potentially dilutive ordinary shares:				
Compensation of employees	393	271	615	387
Weighted average number of ordinary shares used in the computation of diluted earnings per share	100,343	100,221	100,565	100,337

The Company may settle the compensation of employees in cash or shares; therefore, the Company assumes that the entire amount of the compensation will be settled in shares, and the resulting potential shares are included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

25. GOVERNMENT GRANTS

For the six months ended June 30, 2026, the Company received subsidies totaling NT\$130 thousand from the Ministry of Economy Affairs on Dubai International Medical Exhibition. The amounts are included in the “Other Income” line item.

For the six months ended June 30, 2025, the Company received subsidies totaling NT\$119 thousand from the Ministry of Labor for the “Enterprise Human Resources Uplift Program. The amounts are included in the “Other Income” line item.

26. CAPITAL MANAGEMENT

The Company manages its capital to ensure that entities in the group will be able to continue as going concerns while maximizing the return to shareholders through the optimization of the debt and equity balance. The Company's overall strategy remains unchanged.

The capital structure of the Company consists of equity attributable to owners of the parent company (comprising share capital, capital surplus, retained earnings and other equity).

The Company is not subject to any externally imposed capital requirements.

Key management personnel of the Company review the capital structure annually. As part of this review, the key management personnel consider the cost of capital and the risks associated with each class of capital. Based on their recommendations, in order to balance the overall capital structure, the Company through the payment of dividends, issuance of new shares, shares repurchased, and the issuance of new debt or the redemption of existing debt.

27. FINANCIAL INSTRUMENTS

a. Fair value of financial instruments not measured at fair value

The management considers that the carrying amounts of financial assets and financial liabilities that not measured at fair value were approximate their fair values.

b. Fair value of financial instruments measured at fair value on a recurring basis

1) Fair value hierarchy

June 30, 2026

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
<u>Financial assets at FVTPL</u>				
Domestic emerging market shares	\$ -	\$ -	\$ 53,356	\$ 53,356
Domestic unlisted shares	-	-	23,837	23,837
	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 77,193</u>	<u>\$ 77,193</u>

December 31, 2025

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
<u>Financial assets at FVTPL</u>				
Domestic emerging market shares	\$ -	\$ -	\$ 61,164	\$ 61,164
Domestic unlisted shares	-	-	16,111	16,111
	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 77,275</u>	<u>\$ 77,275</u>

June 30, 2025

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
<u>Financial assets at FVTPL</u>				
Domestic emerging market				
shares	\$ -	\$ -	\$ 53,658	\$ 53,658
Domestic and foreign unlisted				
shares	<u>-</u>	<u>-</u>	<u>37,584</u>	<u>37,584</u>
	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 91,242</u>	<u>\$ 91,242</u>

There were no transfers between Level 1 and Level 2 in the current and prior periods.

2) Valuation techniques and inputs applied for Level 3 fair value measurement

- a) Investments in domestic emerging market shares and certain domestic and foreign unlisted equity instruments are measured using the market approach. This approach derives value from the prices of comparable companies, adjusted for differences between the subject asset and its comparables, using appropriate multiples. The significant unobservable inputs are as follows: a decrease in the liquidity discount would result in an increase in the fair value of these investments.

	June 30, 2026	December 31, 2025	June 30, 2025
Discount for lack of marketability	7.96%~30%	7.24%~30%	8.64%

If the inputs to the valuation model were changed to reflect reasonably possible alternative assumptions while all the other variables were held constant, the fair value of the shares would increase (decrease) as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Discount for lack of marketability			
1% increase	<u>(\$ 613)</u>	<u>(\$ 700)</u>	<u>(\$ 587)</u>
1% decrease	<u>\$ 613</u>	<u>\$ 700</u>	<u>\$ 587</u>

- b) Certain domestic unlisted equity instruments are measured using the asset-based approach, which evaluates the total value of individual assets and liabilities to reflect the overall value of the enterprise or business. The significant unobservable inputs are as follows: a decrease in the liquidity discount would result in an increase in the fair value of these investments.

	June 30, 2026	December 31, 2025	June 30, 2025
Discount for lack of marketability	20%	20%	20%

If the inputs to the valuation model were changed to reflect reasonably possible alternative assumptions while all the other variables were held constant, the fair value of the shares would increase (decrease) as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Discount for lack of marketability			
1% increase	(\$ 298)	(\$ 201)	(\$ 155)
1% decrease	\$ 298	\$ 201	\$ 155

c. Categories of financial instruments

	June 30, 2026	December 31, 2025	June 30, 2025
<u>Financial assets</u>			
Financial assets at FVTPL			
Mandatorily classified as at FVTPL	\$ 77,193	\$ 77,275	\$ 91,242
Financial assets measured at amortized cost (Note 1)	1,147,228	1,016,892	1,004,639
<u>Financial liabilities</u>			
Financial liabilities measured at amortized cost (Note 2)	310,075	292,650	245,714

Note 1 : The balances include financial assets at amortized cost, which comprise cash, pledged deposits, notes receivable and accounts receivable (including from related parties), other receivables and refundable deposits.

Note 2 : The balances include financial liabilities at amortized cost, which comprise loans, notes payable, accounts payable (including from related parties), other payables and guarantee deposits received.

d. Financial risk management objectives and policies

The Company's major financial instruments include equity investments, accounts receivable, accounts payable, borrowings and lease liabilities. The Company's corporate treasury function provides services to the business, coordinates access to domestic and international financial markets, and monitors and manages the financial risks relating to the operations of the Company through internal risk reports that analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The corporate treasury function reports quarterly to the Company's management, that monitors risks and policies implemented to mitigate risk exposures.

1) Market risk

The Company's activities exposed it primarily to the financial risks of changes in foreign currency exchange rates (see (a) below) and interest rates (see (b) below).

There has been no change to the Company's exposure to market risks and the manner in which these risks are managed and measured.

a) Foreign currency risk

The carrying amounts of the significant monetary assets and liabilities not denominated in functional currency (including those eliminated on consolidation) at the end of the reporting period are set out in Note 30.

Sensitivity analysis

The Company is mainly exposed to the USD, RMB, EUR and JPY.

The following table details the Company's sensitivity to a 1% increase and decrease in the functional currency against the relevant foreign currencies. The sensitivity rate used when reporting foreign currency risk internally to key management personnel and representing management's assessment of the reasonably possible change in foreign exchange rates is 1%. A positive number below indicates an increase in pre-tax profit with the functional currency weakening 1% against the relevant currency. For a 1% strengthening of the functional currency against the relevant currency, there would be an equal and opposite impact on pre-tax profit, and the balances below would be negative.

	USD Impact		RMB Impact	
	For the Six Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Profit or loss	\$ 1,251	\$ 3,088	\$ 73	\$ 173

	EUR Impact		JPY Impact	
	For the Six Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Profit or loss	\$ 6,560	\$ 3,471	\$ 5	(\$ 6)

b) Interest rate risk

The carrying amount of the Company's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Fair value interest rate risk			
Financial assets	\$ 6,200	\$ 6,200	\$ 6,200
Financial liabilities	106,446	109,674	113,692
Cash flow interest rate risk			
Financial assets	737,168	566,691	583,082

Sensitivity analysis

The sensitivity analysis below was determined based on the Company's exposure to interest rates for non-derivative instruments at the end of the reporting period. For floating rate assets, the analysis was prepared assuming the amount of each liability outstanding at the end of the period was outstanding for the whole year.

If interest rates had been 0.1% higher/lower and all other variables were held constant, the Company's pre-tax profit for the six months ended June 30, 2026 and 2025 would have increased/decreased by NT\$369 thousand and NT\$292 thousand, respectively, which was mainly a result of variable-rate of net assets.

c) Other price risk

The Company was exposed to price risk through equity investments. Equity investments are held for strategic rather than for trading purposes, the Company does not actively trade these investments. The Company's price risk is mainly concentrated in equity investment in Taiwan.

Sensitivity analysis

The sensitivity analysis below was determined based on the exposure to equity price risks at the end of the reporting period.

If equity prices had been 5% higher/lower, pre-tax profit for the six months ended June 30, 2026 and 2025 would have increased/decreased by NT\$3,860 thousand and NT\$4,562 thousand, respectively, as a result of the changes in fair value of financial assets at FVTPL.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in a financial loss to the Company. At the end of the year, the Company's maximum exposure to credit risk, which would cause a financial loss due to the failure of the counterparties to discharge their obligations, is represented by the carrying amounts of the respective recognized financial assets as stated in the consolidated balance sheets.

The Company transacted with a large number of customers from various industries and geographical locations. The Company continuously assesses the financial positions of customers.

The Company's credit risk is mainly concentrated among its top three customers. As of June 30, 2026, December 31, 2025 and June 30 2025, he accounts receivable from these customers accounted for 81%, 84%, and 82% of the total accounts receivable, respectively.

3) Liquidity risk

The Company manages liquidity risk by monitoring and maintaining a level of cash deemed adequate to finance the Company's operations and mitigate the effects of fluctuations in cash flows.

a) Liquidity and interest risk rate table for non-derivative financial liabilities

The following table details the Company's remaining contractual maturities for its non-derivative financial liabilities with agreed upon repayment periods. The table has been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Company can be required to pay. The table includes both interest and principal cash flows. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

June 30, 2026

	Less than 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>			
Lease liabilities	\$ 8,853	\$ 24,795	\$ 115,677
Notes payable	37,666	-	-
Accounts payable	192,298	-	-
Other payables	<u>161,731</u>	<u>-</u>	<u>-</u>
	<u>\$ 400,548</u>	<u>\$ 24,795</u>	<u>\$ 115,677</u>

Further information on the maturity analysis of the above financial liabilities was as follows:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 8,853</u>	<u>\$24,795</u>	<u>\$28,214</u>	<u>\$28,214</u>	<u>\$28,214</u>	<u>\$31,035</u>

December 31, 2025

	Less than 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>			
Lease liabilities	\$ 10,841	\$ 24,717	\$ 118,498
Notes payable	39,187	-	-
Accounts payable	192,508	-	-
Other payables	<u>144,308</u>	<u>-</u>	<u>-</u>
	<u>\$ 386,844</u>	<u>\$ 24,717</u>	<u>\$ 118,498</u>

Further information on the maturity analysis of the above financial liabilities was as follows:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$10,841</u>	<u>\$24,717</u>	<u>\$28,214</u>	<u>\$28,214</u>	<u>\$28,214</u>	<u>\$33,856</u>

June 30, 2025

	Less than 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>			
Lease liabilities	\$ 11,741	\$ 26,670	\$ 121,320
Notes payable	34,491	-	-
Accounts payable	154,745	-	-
Other payables	<u>127,360</u>	<u>-</u>	<u>-</u>
	<u>\$ 328,337</u>	<u>\$ 26,670</u>	<u>\$ 121,320</u>

Further information on the maturity analysis of the above financial liabilities was as follows:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$11,741</u>	<u>\$26,670</u>	<u>\$28,214</u>	<u>\$28,214</u>	<u>\$28,214</u>	<u>\$36,678</u>

b) Financing facilities

	June 30, 2026	December 31, 2025	June 30, 2025
Unsecured bank loan facilities			
Amount used	\$ -	\$ -	\$ -
Amount unused	<u>659,250</u>	<u>657,150</u>	<u>646,500</u>
	<u>\$ 659,250</u>	<u>\$ 657,150</u>	<u>\$ 646,500</u>
Secured bank loan facilities			
Amount used	\$ -	\$ -	\$ -
Amount unused	<u>57,330</u>	<u>56,574</u>	<u>52,740</u>
	<u>\$ 57,330</u>	<u>\$ 56,574</u>	<u>\$ 52,740</u>

28. TRANSACTIONS WITH RELATED PARTIES

Balances and transactions between APEX and its subsidiaries, which are related parties of APEX, have been eliminated on consolidation and are not disclosed in this note. Besides information disclosed elsewhere in the other notes, details of transactions between the Company and other related parties are disclosed as follows.

a. Related party name and category

Related Party Name	Relationship with the Company
METERTECH INC.	Others

b. Sales of goods

Line Item	Related Party Category/Name	For the Three Months Ended June 30		For the Six Months Ended June 30	
		2026	2025	2026	2025
Sales	Others	<u>\$ 103</u>	<u>\$ 51</u>	<u>\$ 162</u>	<u>\$ 51</u>

c. Purchases of goods

Line Item	Related Party Category/Name	For the Three Months Ended		For the Six Months Ended	
		June 30		June 30	
		2026	2025	2026	2025
Cost of goods sold	Others	<u>\$ 316</u>	<u>\$ 75</u>	<u>\$ 1,334</u>	<u>\$ 519</u>

There are no comparable benchmarks available for the purchase prices from related parties. The payment terms for both related and non-related parties are 30 ~ 150 days after the end of the month or upon receipt of goods.

d. Receivables from related parties

Line Item	Related Party Category/ Name	June 30,	December 31,	June 30,
		2026	2025	2025
Notes receivable and accounts receivable	Others	<u>\$ 108</u>	<u>\$ 54</u>	<u>\$ 54</u>

The outstanding accounts receivable from related parties are unsecured.

e. Payables to related parties

Line Item	Related Party Category/ Name	June 30,	December 31,	June 30,
		2026	2025	2025
Accounts payable	Others	<u>\$ -</u>	<u>\$ 487</u>	<u>\$ 79</u>

The outstanding accounts payable to related parties are unsecured and will be settled in cash.

f. Compensation of key management personnel

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2026	2025	2026	2025
Short-term employee benefits	\$ 6,858	\$ 9,176	\$ 14,099	\$ 14,912
Post-employment benefits	<u>156</u>	<u>252</u>	<u>310</u>	<u>305</u>
	<u>\$ 7,014</u>	<u>\$ 9,428</u>	<u>\$ 14,409</u>	<u>\$ 15,217</u>

The remuneration of directors and other key executives, as determined by the remuneration committee, is based on the performance of individuals and market trends.

29. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets have been pledged as security deposits for the land lease with the Hsinchu Science Park Bureau.

	June 30, 2026	December 31, 2025	June 30, 2025
Pledged time deposits (classified as financial assets at amortized cost)	\$ 6,200	\$ 6,200	\$ 6,200

30. SIGNIFICANT ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Company's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Company and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

June 30, 2026

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 5,808	31,850(USD:NTD)	\$ 184,985
USD	198	6.8109(USD:RMB)	6,325
EUR	18,077	36.290	656,014
RMB	1,548	4.6900	7,260
JPY	2,621	0.1963	515
			<u>\$ 855,099</u>
<u>Financial liabilities</u>			
Monetary items			
USD	2,078	31.850	\$ 66,184
JPY	233	0.1963	46
			<u>\$ 66,230</u>

December 31, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 5,084	31.430(USD:NTD)	\$ 159,790
USD	209	7.0288(USD:RMB)	6,605
EUR	9,478	36.900	349,738
RMB	2,856	4.4960	12,841
JPY	5,951	0.2008	<u>1,195</u>
			<u>\$ 530,169</u>
<u>Financial liabilities</u>			
Monetary items			
USD	1,910	31.430	\$ 60,031
JPY	2,702	0.2008	543
EUR	7	36.900	258
GBP	34	42.330	<u>1,439</u>
			<u>\$ 62,271</u>

June 30, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 11,395	29.300(USD:NTD)	\$ 333,874
USD	311	7.1586(USD:RMB)	9,108
EUR	10,106	34.350	347,141
RMB	4,221	4.091	17,268
JPY	791	0.2034	<u>161</u>
			<u>\$ 707,552</u>
<u>Financial liabilities</u>			
Monetary items			
USD	1,167	29.300	\$ 34,193
JPY	3,650	0.2034	<u>742</u>
			<u>\$ 34,935</u>

Realized and unrealized net foreign exchange gains (losses) were NT\$(7,528) thousand and NT\$(49,401) thousand for the three months ended June 30, 2026 and 2025, respectively, and NT\$(4,092) thousand and NT\$(20,906) thousand for the six months ended June 30, 2026 and 2025, respectively. It is impractical to disclose net foreign exchange gains (losses) by each significant foreign currency due to the variety of the foreign currency transactions and functional currencies of the entities in the Group.

31. SEPARATELY DISCLOSED ITEMS

Except for items (a) to (f), there are no other significant transactions, information on investees and information on investment in mainland China that should be disclosed.

a. Financing provided to others

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

No.	Lender	Borrower	Financial Statement Account	Related Party	Highest Balance for the Period	Ending Balance	Actual Amount Borrowed	Interest Rate (%)	Nature of Financing	Business Transaction Amount	Reason for Short-term Financing	Allowance for Impairment Loss	Collateral		Financing Limit for Each Borrower (Note 1)	Aggregate Financing Limit (Note 2)
													Item	Value		
0	APEX	Omnis	Other receivables - related parties	Yes	\$ 47,775 (USD1,500 thousand)	\$ - (USD - thousand)	\$ - (USD - thousand)	3.56%~4.34%	The need for short-term financing	\$ -	Operating capital	\$ -	-	\$ -	\$537,630	\$743,506
		Omnis	Other receivables - related parties	Yes	\$ 41,405 (USD1,300 thousand)	\$ 41,405 (USD1,300 thousand)	\$ 28,665 (USD 900 thousand)	3.59%~4.85%	The need for short-term financing	\$ -	Operating capital	\$ -	-	\$ -	\$537,630	\$743,506

Note 1 : The financing limit for any individual borrower within the Group, in which APEX directly or indirectly holds 20% or more of its voting shares, shall not exceed 30% of APEX's net equity as stated in its latest financial statements.

Note 2 : The aggregate financing limit shall not exceed 40% of APEX's net equity as stated in its latest financial statements.

b. Endorsements/guarantees provided

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

No.	Endorser/ Guarantor	Endorsee/Guarantee		Limit on Endorsement/ Guarantee Given on Behalf of Each Party (Note 1)	Maximum Amount Endorsed/ Guaranteed During the Period	Outstanding Endorsement/ Guarantee at the End of the Period	Actual Amount Borrowed	Amount Endorsed/ Guaranteed by Collateral	Ratio of Accumulated Endorsement/ Guarantee to Net Equity in Latest Financial Statements (%)	Aggregate Endorsement/ Guarantee Limit (Note 2)	Endorsement/ Guarantee Given by Parent on Behalf of Subsidiaries	Endorsement/ Guarantee Given by Subsidiaries on Behalf of Parent	Endorsement/ Guarantee Given on Behalf of Companies in Mainland China
		Name	Relationship										
0	APEX	Omnis	Subsidiary	\$ 371,753	\$ 57,330 (USD 1,800 thousand)	\$ 57,330 (USD 1,800 thousand)	\$ - (USD - thousand)	\$ 57,330	3.08	\$ 929,383	Yes	No	No

Note 1 : The limit on endorsements/guarantees given on behalf of each party shall not exceed 20% of APEX's net equity as stated in latest financial statements.

Note 2 : The aggregate endorsements/guarantees limit shall less than 50% of APEX's net equity as stated in latest financial statements.

c. Significant Marketable securities held

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Holding Company Name	Type and Name of Marketable Securities	Relationship with the Holding Company	Financial Statement Account	June 30, 2026			
				Shares	Carrying Amount	Percentage of Ownership (%)	Fair Value
APEX	Shares : Lytone Enterprise, Inc.	—	FVTPL- current	2,131,800	\$ 43,766	12	\$ 43,766
	Shares : Ascendax Venture Capital Corporation	—	FVTPL- current	1,263,940	23,837	2	23,837
	Shares : H2 INC.	—	FVTPL- current	439,716	9,590	1	9,590

Note1 : The marketable securities listed above were not pledged, guarantees or otherwise restricted by contract as of June 30, 2026.

Note2 : This table presents the marketable securities that the Company has determined should be disclosed based on the materiality principle.

d. Intercompany relationships and significant intercompany transactions

For the Six Months Ended June 30, 2026

No.	Investee Company	Counterparty	Relationship (Note 1)	Transaction Details			
				Financial Statement Accounts	Amount	Payment Terms (Note 2)	% to Total Sales or Assets
0	APEX	APEX(Suzhou)	1	Sales	\$ 6,670	—	0.67%
				Net receivables -related parties	4,055	—	0.16%
				Purchase	292	—	0.03%
		Omnis	1	Sales	56,691	—	5.72%
				Other operating revenue	337	—	0.03%
				Interest revenue	580	—	0.06%
				Net receivables -related parties	46,805	—	1.84%
1	APEX(Suzhou)	Omnis	2	Other receivables - related parties	29,174	—	1.14%
				Sales	11,527	—	1.16%
				Net receivables -related parties	3,057	—	0.12%

Note 1 : The transactions from the parent company to the subsidiary are denoted as 1. The transactions between two subsidiaries are denoted as 2.

Note 2 : The Company has no appropriate comparable prices for sales to its subsidiaries. The collection period for these subsidiaries ranges from 120 to 150 days from the end of the month.

Note 3 : The significant transactions in this table may be determined by the Company based on the principle of materiality.

e. Information on investees

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of June 30, 2026			Net Income (Loss) of the Investee	Share of Profit (Loss)
				June 30, 2026	December 31, 2025	Shares/Units	(%)	Carrying Amount		
APEX	Omnis	USA	Wholesale of medical consumable and medical equipment	\$ 526,613	\$ 526,613	70,312,094	99	\$ 38,605	\$ 11,032	\$ 10,909

f. Information on investment in mainland China

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Investee Company	Main Businesses and Products	Paid-in Capital	Method of Investment	Accumulated Outward Remittance for Investment from Taiwan as of January 1, 2026	Remittance of Funds		Accumulated Outward Remittance for Investment from Taiwan as of June 30, 2026	Net Income (Loss) of the Investee	% Ownership of Direct or Indirect Investment	Investment Gain (Loss)	Carrying Amount as of June 30, 2026	Accumulated Repatriation of Investment Income as of June 30, 2026
					Outward	Inward						
APEX (Suzhou)	Wholesale of medical consumable and medical equipment	\$ 35,394 (RMB 7,000 thousand)	(Note 1)	\$ 33,975 (RMB 6,700 thousand)	\$ -	\$ -	\$ 33,975 (RMB 6,700 thousand)	\$ 1,949	96%	\$ 826	\$11,245	\$ -

Accumulated Outward Remittance for Investment in Mainland China as of June 30, 2026	Investment Amount Authorized by the Investment Commission, MOEA	Upper Limit on the Amounts of Investment Stipulated by Investment Commission, MOEA
\$33,975 (RMB 6,700 thousand)	\$33,975 (RMB 6,700 thousand)	\$1,115,260

Note 1 : Direct investment in mainland China.

Note 2 : The amount was recognized based on the unreviewed financial statements of the investee company.

32. SEGMENT INFORMATION

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the types of products. Each product has similar economic characteristics and sales through the centralized sales approach, thus, the Company aggregated into a one operating segment. The segment information presented to the chief operating decision maker are consistent with the information in the financial statements. The segment revenues and operating results for the six months ended June 30, 2026 and 2025 are shown in the consolidated comprehensive income statements for the six months ended June 30, 2026 and 2025. The segment assets as of June 30, 2026, December 31, 2025, and June 30, 2025 are shown in the consolidated balance sheets as of June 30, 2026, December 31, 2025, and June 30, 2025.